କିଡନୀ କ୍ୟାନ୍ସର
A Study to Compare Gastrointestinal Adverse Events of Two Cabozantinib Tablet Types in Adult patients With Advanced or Metastatic Kidney Cancer
ହସ୍ପିଟାଲ ସହିତ ଯୋଗାଯୋଗ କରନ୍ତୁ
ରେଜିଷ୍ଟ୍ରି ଏହି ହସ୍ପିଟାଲକୁ ଟ୍ରାଏଲର ମୁଖ୍ୟ ଯୋଗାଯୋଗ ଭାବରେ ନାମିତ କରିଛି। ସେମାନଙ୍କୁ ପଚାରନ୍ତୁ କେଉଁ ହସ୍ପିଟାଲ ରୋଗୀ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
A Phase 2/3 Randomized, Parallel, Multicenter, Safety Study to Evaluate Gastrointestinal Adverse Events of Azurity Cabozantinib Tablets vs. CABOMETYX® (cabozantinib) Tablets as a Single-Agent in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma - NIL
Sponsor: Azurity Pharmaceuticals, Inc.
CTRI, India's trial registry ରେ CTRI/2025/11/097766
Source: Clinical Trials Registry – India (CTRI), WHO ICTRP ମାଧ୍ୟମରେ, 12 Oct 2026 ର ତଥ୍ୟ
Last updated on the registry 22 Jun 2026 · read by us 5 Nov 2026